Cursus Bio

Cursus Bio is a South Korean private biotech and drug-delivery company developing dissolving microneedle patch technologies and adipocyte-targeted non-viral gene therapies for obesity and metabolic disease. The company appears to be a Hanyang University spin-out and has been described as a subsidiary or affiliated investee of iCure Pharmaceutics. Its lead program is an adipocyte-targeted anti-obesity gene therapy designed to silence FABP4 and FABP5, with administration options including injectable and transdermal microneedle patch delivery. Cursus Bio's core platform, MicroLock, is a self-locking, quantitative transdermal microneedle patch technology being applied to both pharmaceutical and cosmetic products. The company also reports OEM/ODM activities supported by CGMP-certified manufacturing facilities for microneedle cosmetics and pharmaceuticals.